KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Equity Income (2018 - 2020)

Arbutus Biopharma's Equity Income history spans 3 years, with the latest figure at -$2.5 million for Q3 2020.

  • For Q3 2020, Equity Income rose 27.53% year-over-year to -$2.5 million; the TTM value through Sep 2021 reached -$2.5 million, up 88.55%, while the annual FY2020 figure was -$2.5 million, 88.7% up from the prior year.
  • Equity Income for Q3 2020 was -$2.5 million at Arbutus Biopharma, up from -$19.7 million in the prior quarter.
  • Across five years, Equity Income topped out at $24.9 million in Q2 2018 and bottomed at -$19.7 million in Q4 2019.
  • The 3-year median for Equity Income is -$3.3 million (2019), against an average of -$1.7 million.
  • The largest annual shift saw Equity Income tumbled 113.39% in 2019 before it increased 27.53% in 2020.
  • A 3-year view of Equity Income shows it stood at -$2.8 million in 2018, then plummeted by 593.59% to -$19.7 million in 2019, then skyrocketed by 87.07% to -$2.5 million in 2020.
  • Per Business Quant, the three most recent readings for ABUS's Equity Income are -$2.5 million (Q3 2020), -$19.7 million (Q4 2019), and -$3.5 million (Q3 2019).